Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies

Inclusion Criteria:

- Have a histological or cytological diagnosis of malignant solid neoplasm requiring
systemic chemotherapy.

- Age ≥18 years.

- ECOG performance status 0-1.

- Adequate organ function.

- Adequate hematological function.

- Have the ability to understand the requirements of the study, provide written
informed consent, and comply with the study protocol procedures.

- Consent to collection of previously obtained, archival biopsy or surgical specimens
of the currently treated malignancy when available.

Exclusion Criteria:

- Significant cardiac disease.

- Eye trauma or disease.

- Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months
prior to first dose of HGS1036.

- Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of
HGS1036.

- Major surgery within 4 weeks of the first dose of HGS1036.

- Prior organ or allogeneic stem cell transplant.

- Non-healing or chronic wounds.

- Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.

- Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of
the first dose of HGS1036.

- Active CNS involvement by primary or metastatic tumor.

- Documented active infection requiring the use of systemic antibiotics.

- Pregnancy or lactation.

- Known HIV-positive serology, AIDS, or an AIDS-related illness.

- Conditions likely to increase the potential for abdominal perforation or fistula
formation.